{
    "clinical_study": {
        "@rank": "159633", 
        "arm_group": {
            "arm_group_label": "Concomitant Group", 
            "arm_group_type": "Experimental", 
            "description": "concomitant administration of mirabegron to solifenacin treated patients"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of concomitant use of\n      mirabegron in patients with overactive bladder under treatment with solifenacin."
        }, 
        "brief_title": "A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Overactive Bladder", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder, Overactive"
        }, 
        "detailed_description": {
            "textblock": "The duration of the study will be a total of 18 weeks including a 2-week screening period\n      and 16 week treatment period. At week 8 visit, the dose of mirabegron can be increased based\n      on agreement of the subject if mirabegron, in the opinion of the investigator or\n      sub-investigator, is not fully effective."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female: postmenopausal OAB outpatient\n\n          -  Male: OAB outpatient who has no wish to have children in the future\n\n          -  Patient has been under treatment with solifenacin at a stable dose once daily for at\n             least 4 weeks prior to the study\n\n          -  Patient has a total OABSS score of \u22653 points and a Question 3 score \u22652 points\n\n        Exclusion Criteria:\n\n          -  Patient has a residual urine volume of \u2265100 mL or a maximum flow rate <5 mL/s, or\n             patients with benign prostatic hyperplasia, or lower urinary tract obstruction\n\n          -  Patient has serious heart disease (myocardial infarction, cardiac failure,\n             uncontrolled angina pectoris, serious arrhythmia, use of pacemaker, etc.), liver\n             disease, kidney disease, immunological disease, lung disease, etc. or patient has\n             malignant tumor (except for malignant tumor that has not been treated for at least 5\n             y before the start of the screening period with no risk of recurrence)\n\n          -  Patient has received surgical therapy that may affect the urinary tract function\n             within 24 wk before the start of the screening period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01745094", 
            "org_study_id": "178-CL-110"
        }, 
        "intervention": [
            {
                "arm_group_label": "Concomitant Group", 
                "description": "oral", 
                "intervention_name": "mirabegron", 
                "intervention_type": "Drug", 
                "other_name": [
                    "YM178", 
                    "Betanis"
                ]
            }, 
            {
                "arm_group_label": "Concomitant Group", 
                "description": "oral", 
                "intervention_name": "solifenacin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "YM905", 
                    "Vesicare"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "solifenacin", 
            "mirabegron"
        ], 
        "lastchanged_date": "December 6, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chubu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansai", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kantou", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyushu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Post-Marketing Clinical Study of Mirabegron -Add-on Therapy With Mirabegron in Patients With Overactive Bladder Under Treatment With Solifenacin-", 
        "overall_contact": {
            "email": "clintrialtrials_info@jp.astellas.com", 
            "last_name": "Clinical Development Administration Dept."
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety assessed by the incidence of adverse events, vial signs labo-tests, 12-lead ECGs, QTc-intervals Urine volume and uroflowmetry", 
            "safety_issue": "No", 
            "time_frame": "for 16 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01745094"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in OABSS (OverActive Bladder Symptom Score)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 16"
            }, 
            {
                "measure": "Change from baseline in OAB-q (OverActive Bladder questionnaire) short form (QAB-q SF) score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 16"
            }, 
            {
                "measure": "Change from baseline in mean number of micturition episodes per 24 hour", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 16"
            }, 
            {
                "measure": "Change from baseline in mean number of urgency episodes per 24 hours", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 16"
            }, 
            {
                "measure": "Change from baseline in mean number of urinary incontinence episodes per 24 hours", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 16"
            }, 
            {
                "measure": "Change from baseline in mean volume voided per micturition", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 16"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}